China is teeming with promising science in areas such as oncology and immunology ... comes not only from other VC firms or even biotech companies. It’s coming from big pharma, he said.

Immunology is a rapidly advancing field with significant potential for growth, especially in the realm of biotech and pharmaceutical companies. As the global demand for innovative treatments for ...

One takeaway from the ongoing biotech IPO drought is that companies should have at least ... development of a pipeline of inflammation and immunology (I&I) drugs, including a lead program that ...

Its immunology drug Dupixent is approved to ... Unlike many unprofitable biotech companies, Regeneron was in the “green” and generated $4.3 billion in net income in 2022.

Shares Biotechnology ETF offers efficient, diversified exposure to the sector's revival, balancing risk and cost for ...

Drug developers aren’t expected to come back to the US equity markets in full force until next year — lagging other ...

GlycoEra’s lead candidate targets IgG4 autoantibodies, potentially addressing autoimmune diseases such as muscle-specific ...

With the new fund, Arch plans to invest in companies addressing infectious disease, mental health, immunology ... remains bullish on opportunity in the biotech market. "All the fundamental ...

The number of smid-cap biotech companies with market caps at or below ... Pfizer is launching several potential blockbusters in cancer and immunology. Data on Pfizer's obesity-drug candidate ...